Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-GARP
- Development stage
- Preclinical
- Lead developer
- Henlius
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intracavitary
01
Overview
Anti-GARP refers to a class of therapeutic agents, including monoclonal antibodies and chimeric antigen receptor (CAR) T-cell therapies, that target Glycoprotein A Repetitions Predominant (GARP, also known as LRRC32). GARP is a transmembrane protein primarily expressed on activated regulatory T cells (Tregs), platelets, and certain tumor cells. It functions as a docking receptor for latent transforming growth factor-beta (TGF-β), facilitating its activation and release. By targeting GARP, these therapies aim to inhibit the immunosuppressive effects of TGF-β within the tumor microenvironment, thereby restoring anti-tumor T-cell activity. Some anti-GARP antibodies, such as DS-1055a, also work by depleting GARP-expressing Tregs through antibody-dependent cellular cytotoxicity (ADCC). Several candidates are in clinical development, including Henlius's HLX60 and Daiichi Sankyo's DS-1055a, for the treatment of advanced solid tumors, lymphomas, and gliomas.
- Other names
- anti-LRRC32anti-LRRC-32anti-LRRC 32anti-glycoprotein-A repetitions predominantanti-GARP antibodyanti-GARP CAR-T
02
Targets
TGFB (GARP–latent transforming growth factor beta 1 complex)LRRC32 (GARP)
Beyond the preview
Go deeper on anti-GARP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-GARP.